Neural cell extracellular vesicles

A pharmaceutical composition comprising a therapeutically effective amount of extracellular vesicles (EVs) obtained from non-transformed human neural progenitor cells that are capable of differentiating into neurons, astrocytes and oligodendrocytes in vitro, and a pharmaceutically acceptable carrier, wherein the EVs comprise melanoma-associated chondroitin sulfate proteoglycan (MCSP), pentraxin-3 (PTX3), angiopoietin-1, insulin-like growth factor-binding protein 2 (IGFBP2), macrophage colony-stimulating factor, and ecto-5′-nucleotidase (NT5E), and wherein the EVs comprise an exogenous agent selected from the group consisting of an siRNA, an antisense oligonucleotide, a peptide, a protein, an antibody, and a small molecule.